1st Circ. Won't Rethink Ending Sarepta Securities Suit
By Bryan Koenig ( October 12, 2017, 2:06 PM EDT) -- The First Circuit refused Wednesday to reconsider its August decision upholding the dismissal of a putative securities class action accusing drugmaker Sarepta Therapeutics Inc. of misleading investors over the possibility of government approval for its muscular dystrophy drug eteplirsen....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.